2016 Sep 19
The impact of Tecentriq to treat patients with advanced bladder cancer
The immunotherapy Tecentriq (atezolizumab) has been found to be non-toxic and has demonstrated a major survival advantage in patients with metastatic urothelial bladder cancer, according to David Nanus, M.D. Read more




















